Ibrutinib in Waldenstrom macroglobulinemia: Latest evidence and clinical experience Journal Article
| Authors: | Castillo, J. J.; Palomba, M. L.; Advani, R.; Treon, S. P. |
| Article Title: | Ibrutinib in Waldenstrom macroglobulinemia: Latest evidence and clinical experience |
| Abstract: | Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenstrom macroglobulinemia (WM). Herein, we review the role of BTK in the pathophysiology of WM, and present the results of the preclinical and clinical studies that led to the initial investigation and later approval of ibrutinib in WM. We also discuss aspects associated with ibrutinib therapy in WM patients, especially focusing on genomic profiling and the impact on response to ibrutinib, and the management of adverse events. |
| Keywords: | rituximab; dexamethasone; lymphoma; innate immunity; chronic lymphocytic-leukemia; primary therapy; end results database; atrial-fibrillation; bruton tyrosine kinase; waldenstrom macroglobulinemia; whim-syndrome; bruton's tyrosine kinase; ibrutinib; lymphoplasmacytic lymphoma; mantle-cell |
| Journal Title: | Therapeutic Advances in Hematology |
| Volume: | 7 |
| Issue: | 4 |
| ISSN: | 2040-6207 |
| Publisher: | Sage Publications |
| Date Published: | 2016-08-01 |
| Start Page: | 179 |
| End Page: | 186 |
| Language: | English |
| ACCESSION: | WOS:000383653400001 |
| DOI: | 10.1177/2040620716654102 |
| PROVIDER: | wos |
| PMCID: | PMC4959643 |
| PUBMED: | 27493708 |
| Notes: | Review -- Source: Wos |
